Immorta Bio is a Miami Beach–based biotechnology company focused on reversing aging by developing two key therapeutic platforms. Its StemCell Revivify™ program uses patient-specific induced pluripotent stem cells to create rejuvenated stem cell therapies aimed at restoring youthful tissue function. The second platform, SenoVax™, is a novel senolytic immunotherapy designed to train the immune system to identify and eliminate senescent cells, which are linked to aging and disease progression. Founded in 2023, the company has shown promising preclinical results and is preparing for human trials targeting conditions such as liver failure and lung cancer.